Patents by Inventor Mark Millan

Mark Millan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20060223830
    Abstract: A compound selected from those of formula (I): wherein: R3 represents a hydrogen atom, and R1 and R2 together with the carbon atoms carrying them form a benzene, naphthalene or quinoline ring structure, each of the ring structures being optionally substituted, ?or R1 represents a hydrogen atom, and R2 and R3 together with the carbon atoms carrying them form a benzene, naphthalene or quinoline ring structure, each of the ring structures being optionally substituted, n represents 1 or 2, —X— represents a group selected from —(CH2)m—O-Ak-, —(CH2)m—NR4-Ak-, —(CO)—NR4-Ak- and —(CH2)m—NR4-(CO)—, ?m represents an integer between 1 and 6 inclusive, Ak represents an optionally substituted alkylene chain, and R4 represents a hydrogen atom or an alkyl group, Ar represents an aryl or heteroaryl group, its enantiomers, diasteroisomers, and addition salts thereof with a pharmaceutically acceptable acid.
    Type: Application
    Filed: March 29, 2006
    Publication date: October 5, 2006
    Inventors: Guillaume De Nanteuil, Bernard Portevin, Philippe Gloanec, Mark Millan, Jean-Claude Ortuno, Clotilde Mannoury La Cour, Alain Gobert
  • Patent number: 7053108
    Abstract: A compound of formula (I): wherein: R1 and R2 together form a benzo ring optionally substituted by halogen or by alkyl, alkoxy, cyano, nitro, hydroxy, amino, alkylamino, dialkylamino or trifluoromethyl, and R3 represents hydrogen, or R1 represents hydrogen, and R2 and R3 together form a benzo ring optionally substituted by halogen or by alkyl, alkoxy, cyano, nitro, hydroxy, amino, alkylamino, dialkylamino or trifluoromethyl, its enantiomers, diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base, and medicaments.
    Type: Grant
    Filed: March 30, 2004
    Date of Patent: May 30, 2006
    Assignee: Les Laboratoires Servier
    Inventors: Gilbert Lavielle, Olivier Muller, Mark Millan, Alain Gobert
  • Patent number: 7026357
    Abstract: Compound of formula (I): and medicinal products containing the same are useful as dual ?2/5-HT2c antagonist receptors.
    Type: Grant
    Filed: June 7, 2004
    Date of Patent: April 11, 2006
    Assignee: Les Laboratoires Servier
    Inventors: Gilbert Lavielle, Olivier Muller, Mark Millan, Anne Dekeyne, Mauricette Brocco
  • Patent number: 6998403
    Abstract: A compound of formula (I): wherein: R1 and R2 together form a benzo ring optionally substituted by halogen or by alkyl, alkoxy, cyano, nitro, hydroxy, amino, alkylamino, dialkylamino or trifluoromethyl, and R3 and R4 represent hydrogen, or R1 and R4 represent hydrogen and R2 and R3 together form a benzo ring optionally substituted by halogen or by alkyl, alkoxy, cyano, nitro, hydroxy, amino, alkylamino, dialkylamino or trifluoromethyl, or R1 and R2 represent hydrogen and R3 and R4 together form a benzo ring optionally substituted by halogen or by alkyl, alkoxy, cyano, nitro, hydroxy, amino, alkylamino, dialkylamino or trifluoromethyl, addition salts thereof with a pharmaceutically acceptable acid or base, and methods of treating conditions susceptible to ?2-AR/5-HT2C antagonists.
    Type: Grant
    Filed: August 25, 2004
    Date of Patent: February 14, 2006
    Assignee: Les Laboratoires Servier
    Inventors: Gilbert Lavielle, Olivier Muller, Mark Millan, Alain Gobert, Benjamin Di Cara
  • Publication number: 20050059675
    Abstract: A compound of formula (I): wherein: R1 and R2 together form a benzo ring optionally substituted by halogen or by alkyl, alkoxy, cyano, nitro, hydroxy, amino, alkylamino, dialkylamino or trifluoromethyl, and R3 and R4 represent hydrogen, or R1 and R4 represent hydrogen and R2 and R3 together form a benzo ring optionally substituted by halogen or by alkyl, alkoxy, cyano, nitro, hydroxy, amino, alkylamino, dialkylamino or trifluoromethyl, or R1 and R2 represent hydrogen and R3 and R4 together form a benzo ring optionally substituted by halogen or by alkyl, alkoxy, cyano, nitro, hydroxy, amino, alkylamino, dialkylamino or trifluoromethyl, addition salts thereof with a pharmaceutically acceptable acid or base, and methods of treating conditions susceptible to ?2-AR/5-HT2C antagonists.
    Type: Application
    Filed: August 25, 2004
    Publication date: March 17, 2005
    Inventors: Gilbert Lavielle, Olivier Muller, Mark Millan, Alain Gobert, Benjamin Di Cara
  • Publication number: 20040224993
    Abstract: Compound of formula (I): 1
    Type: Application
    Filed: June 7, 2004
    Publication date: November 11, 2004
    Inventors: Gilbert Lavielle, Olivier Muller, Mark Millan, Anne Dekeyne, Mauricette Brocco
  • Publication number: 20040192736
    Abstract: A compound of formula (I): 1
    Type: Application
    Filed: March 30, 2004
    Publication date: September 30, 2004
    Inventors: Gilbert Lavielle, Olivier Muller, Mark Millan, Alain Gobert
  • Patent number: 6784183
    Abstract: Compounds of formula (I): and medicinal products containing the same which are useful as dual &agr;2/5-HT2c antagonists.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: August 31, 2004
    Assignee: Les Laboratoires Servier
    Inventors: Gilbert Lavielle, Olivier Muller, Mark Millan, Anne Dekeyne, Mauricette Brocco
  • Patent number: 6759421
    Abstract: A compound of formula (I): wherein: R1 and R2 together form a benzo ring optionally substituted by halogen or by alkyl, alkoxy, cyano, nitro, hydroxy, amino, alkylamino, dialkylamino or trifluoromethyl, and R3 represents hydrogen, or R1 represents hydrogen, and R2 and R3 together form a benzo ring optionally substituted by halogen or by alkyl, alkoxy, cyano, nitro, hydroxy, amino, alkylamino, dialkylamino or trifluoromethyl, its enantiomers, diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base, and medicaments.
    Type: Grant
    Filed: March 27, 2003
    Date of Patent: July 6, 2004
    Assignee: Les Laboratoires Servier
    Inventors: Gilbert Lavielle, Olivier Muller, Mark Millan, Alain Gobert
  • Patent number: 6747032
    Abstract: Compound of formula (I): wherein: R1, R2, R3 and R4, which may be the same or different, each represent a hydrogen atom, a halogen atom or a group selected from alkyl, alkoxy, polyhaloalkyl, hydroxy, cyano, nitro and amino,  or R1 with R2, R2 with R3, or R3 with R4, together with the carbon atoms carrying them, form an optionally substituted benzene ring or an optionally substituted heteroaromatic ring, X represents an oxygen atom or a methylene group, A represents an alkylene chain,  represents an optionally substituted, unsaturated, nitrogen-containing heterocycle and R5 represents an alkyl group, its enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid, a medicinal products containing the same are useful as a double &agr;2/5-HT2c antagonist.
    Type: Grant
    Filed: April 18, 2002
    Date of Patent: June 8, 2004
    Assignee: Les Laboratoires Servier
    Inventors: Gilbert Lavielle, Thierry Dubuffet, Olivier Muller, Mark Millan, Anne Dekeyne, Mauricette Brocco
  • Patent number: 6743818
    Abstract: A compound selected from those of formula (I): wherein: n represents integer from 0 to 6, R1 represents a group selected from hydrogen, hydroxy, cyano, alkoxy, alkoxycarbonyl, carboxy, optionally substituted aminocarbonyl, and NR4R5 wherein R4, and R5 are as defined in the description, R2 represents a group selected from hydrogen, alkyl, hydroxymethyl, and —U—V—W wherein T, U, V, and W are as defined in the description, and R3 represents a group selected from hydrogen, linear or branched (C1-C6)alkyl, aryl, and, heteroaryl, its isomers, and also addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same are useful in the treatment of CNS disorders.
    Type: Grant
    Filed: July 12, 2002
    Date of Patent: June 1, 2004
    Assignee: Les Laboratoires Servier
    Inventors: Jean-Louis Peglion, Bertrand Goument, Mark Millan, Françoise Lejeune, Didier Cussac
  • Publication number: 20030199555
    Abstract: A compound of formula (I): 1
    Type: Application
    Filed: March 27, 2003
    Publication date: October 23, 2003
    Inventors: Gilbert Lavielle, Olivier Muller, Mark Millan, Alain Gobert
  • Publication number: 20030087916
    Abstract: Compound of formula (I): 1
    Type: Application
    Filed: April 18, 2002
    Publication date: May 8, 2003
    Inventors: Gilbert Lavielle, Thierry Dubuffet, Olivier Muller, Mark Millan, Anne Dekeyne, Mauricette Brocco
  • Publication number: 20030032812
    Abstract: A compound selected from those of formula (I): 1
    Type: Application
    Filed: July 12, 2002
    Publication date: February 13, 2003
    Inventors: Jean-Louis Peglion, Bertrand Goument, Mark Millan, Francoise Lejeune, Didier Cussac
  • Patent number: 6492366
    Abstract: A compound selected from those of formula (I): wherein: R1 and R2 each independently represent hydrogen or, alkyl, T1 and T2 each independently represent alkylene, G represents a heterocyclic group selected of formula (&agr;):  wherein: W1 to W5 and X1 to X4 are so defined in the description. Medicinal products containing the same are useful as serotonin-reuptake inhibitors.
    Type: Grant
    Filed: October 11, 2000
    Date of Patent: December 10, 2002
    Assignee: Les Laboratoires Servier
    Inventors: Gilbert Lavielle, Olivier Muller, Mark Millan, Didier Cussac, Anne Dekeyne
  • Patent number: 6486171
    Abstract: A compound selected from those of formula (I): wherein: W represents optionally substituted naphthyl, or a group of formula Y (wherein)  as defined in the description, n represents an integer from 1 to 6 inclusive, Z represents a single bond, oxygen, or optionally substituted nitrogen, A and Q each represent CH or nitrogen, it being understood that A or Q must be N and the other CH, M, together with a carbon of the phenyl to which it is bonded, represents thienyl, furyl, pyrrolyl, or oxopyrrolyl, its isomers, and pharmaceutically-acceptable acid or base addition salts thereof, and medicinal products containing the same, which are useful in the treatment of some CNS disorders.
    Type: Grant
    Filed: March 25, 2002
    Date of Patent: November 26, 2002
    Assignee: Les Laboratoires Servier
    Inventors: Jean-Louis Peglion, Aimée Dessinges, Christophe Poitevin, Mark Millan, Anne Dekeyne
  • Publication number: 20020161228
    Abstract: A compound selected from those of formula (I): 1
    Type: Application
    Filed: March 25, 2002
    Publication date: October 31, 2002
    Applicant: ADIR ET COMPAGNIE
    Inventors: Jean Louis Peglion, Aimee Dessinges, Christophe Poitevin, Mark Millan, Anne Dekeyne
  • Patent number: 6452015
    Abstract: A compound selected from those of formula (I): wherein: n represents integer from 0 to 6, R1 represents a group selected from hydrogen, hydroxy, cyano, alkoxy, alkoxycarbonyl, carboxy, optionally substituted aminocarbonyl, and NR4R5 wherein R4, and R5 are as defined in the description, R2 represents a group selected from hydrogen, alkyl, hydroxymethyl,  and -U-V-W wherein T, U, V, and W are as defined in the description, and R3 represents a group selected from hydrogen, linear or branched (C1-C6)alkyl, aryl, and, heteroaryl, its isomers, and also addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same are useful in the treatment of CNS disorders.
    Type: Grant
    Filed: April 12, 2001
    Date of Patent: September 17, 2002
    Assignee: Les Laboratoires Servier
    Inventors: Jean-Louis Peglion, Bertrand Goument, Mark Millan, Françoise Lejeune, Didier Cussac
  • Patent number: 6420413
    Abstract: A compound selected from those of formula (I): wherein: denotes single bond or double bond, n is integer from 1 to 6 inclusive, R1, and R2 represent a group selected from hydrogen, linear or branched (C1-C6)-alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, and heteroarylalkyl, X represents a group selected from —CH═CH—, oxygen, S(O)m wherein m is integer from 0 to 2 inclusive, and NR3 wherein R3 represents a group as defined in the description, Y represents CH or CH2 depending on whether denotes single bond or double bond, or may have the additional meaning of oxygen when X represents oxygen, T represents monocyclic or polycyclic (C3-C10)cycloalkyl optionally containing within the ring system oxygen, selenium, S(O)p, NR3, or SiR4R5 wherein p, R3, R4, and R5 are as defined in the description, its isomers and addition salts thereof with a pharmaceutically-accep
    Type: Grant
    Filed: April 12, 2001
    Date of Patent: July 16, 2002
    Assignee: Les Laboratories Servier
    Inventors: Jean-Louis Peglion, Aimée Dessinges, Bertrand Goument, Mark Millan, Françoise Lejeune, Mauricette Brocco
  • Patent number: 6399616
    Abstract: A compound selected from those of formula (I): wherein: W represents optionally substituted naphthyl, n represents an integer from 2 to 3 inclusive, Z represents a single bond, A represents nitrogen, Q represents nitrogen, M, together with the carbon of pyridyl to which it is bonded, represents thieno, furo, pyrrolo or oxopyrrolo, Its optical isomers and pharmaceutically-acceptable acid or base additional salts thereof, and Medicinal products containing the same which are useful in the treatment of CNS disorders. It being understood that “aryl” is phenyl, naphthyl, dihydronaphthyl, or tetrahydronaphthyl.
    Type: Grant
    Filed: August 18, 2000
    Date of Patent: June 4, 2002
    Assignee: Les Laboratoires Servier
    Inventors: Jean-Louis Peglion, Aimée Dessinges, Christophe Poitevin, Mark Millan, Anne Dekeyne